HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Targeting CD133high Colorectal Cancer Cells In Vitro and In Vivo With an Asymmetric Bispecific Antibody.

Abstract
A critical obstacle in advanced colorectal cancer (CRC) treatment is the insufficient improvement on survival of conventional chemotherapy. Cancer stem cells are reported to be one of the crucial explanations. CD133 has been identified as a surface marker of CRC stem cells. Bispecific antibodies (BiAbs) targeting tumor-specific antigens are promising therapeutics for malignant diseases, yet that targeting CD133 produced by genetic engineering has not been published. In the current research, CD133 expression in primary CRC was detected by immunohistochemistry, and an asymmetric BiAb consisting of monomer of chimeric AC133 (mouse anti-human CD133 monoclonal antibody) and single chain of humanized OKT3 was developed to eradicate CD133-expressing tumor cells by arming activated T cells in vitro and in vivo. In immunohistochemical examination, CD133 overexpression (>50% of stained cells) frequency was significantly correlated with lymphatic invasion and clinical stage. The new molecular revealed dual-antigen-binding specificity to CD133 and CD3, its distinct structure not only facilitated the purification procedure but also conferred the antibody to ensure a longer and stronger cytotoxic activity. By arming activated T cells, the new antibody displayed impressive cytotoxicity toward CD133(high) but not CD133(low) CRC cells in vitro, produced amounts of cytokines (interferon-γ and granulocyte-macrophage colony-stimulating factor), and could inhibit tumor growth and retard tumor development in nonobese diabetic-severe combined immunodeficient mice without apparent toxicity. Taken together, the new BiAb possesses prosperities that support that the molecule has the potential of being a promising candidate of new therapeutics for CRC therapy.
AuthorsLei Zhao, Yudan Yang, Pengfei Zhou, Hong Ma, Xiaolai Zhao, Xin He, Tao Wang, Jing Zhang, Yang Liu, Tao Zhang
JournalJournal of immunotherapy (Hagerstown, Md. : 1997) (J Immunother) 2015 Jul-Aug Vol. 38 Issue 6 Pg. 217-28 ISSN: 1537-4513 [Electronic] United States
PMID26049545 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • AC133 Antigen
  • Antibodies, Bispecific
  • Antibodies, Monoclonal
  • Antigens, CD
  • CD3 Complex
  • Glycoproteins
  • PROM1 protein, human
  • Peptides
  • Prom1 protein, mouse
  • Interferon-gamma
  • Granulocyte-Macrophage Colony-Stimulating Factor
Topics
  • AC133 Antigen
  • Animals
  • Antibodies, Bispecific (genetics, metabolism)
  • Antibodies, Monoclonal (administration & dosage, genetics, immunology)
  • Antigens, CD (metabolism)
  • CD3 Complex (genetics, metabolism)
  • Colorectal Neoplasms (immunology, therapy)
  • Cytotoxicity, Immunologic
  • Genetic Engineering
  • Glycoproteins (metabolism)
  • Granulocyte-Macrophage Colony-Stimulating Factor (metabolism)
  • HCT116 Cells
  • HEK293 Cells
  • HT29 Cells
  • Humans
  • Immunotherapy (methods)
  • In Vitro Techniques
  • Interferon-gamma (metabolism)
  • Mice, SCID
  • Molecular Targeted Therapy
  • Peptides (metabolism)
  • T-Lymphocytes (immunology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: